Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Epidermal Growth Factor Receptor Dependence In Human Tumors: More Than Just Expression?
Published 2002 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The epidermal growth factor receptor (EGFR) is a rational target for antitumor strategies. EGFR signaling causes increased proliferation, decreased apoptosis, and enhanced tumor cell motility and neo-angiogenesis. The EGFR is expressed or highly expressed in a variety of human tumors of epithelial origin. ZD1839 (Iressa) is an orally active, selective EGFR tyrosine kinase inhibitor, which blocks signal transduction pathways implicated in proliferation and survival of cancer cells. The lack of a consistent method of evaluating levels of EGFR has caused a disparity in reports of the EGFR as a prognostic factor; however, for some tumors, EGFR is a strong prognostic indicator associated with more aggressive disease and reduced survival. So far, no clear association between EGFR levels and response to EGFR-targeted agents has been found. Preclinical studies with ZD1839 have noted a relationship between the two in some cases, but not others. EGFR signaling may be increased by a number of mechanisms in addition to high expression levels of EGFR, including receptor mutations, heterodimerization with other members of this receptor family such as HER2 (erbB2), increased expression of (autocrine/ paracrine) ligands, and alterations in molecules that control receptor signaling output. Each of these components could be assessed to give an indication of the magnitude of EGFR signal amplification. Evaluation of signaling components downstream from EGFR should provide information on the activation of the EGFR pathway. Until EGFR-based assays predictive of a response to receptor-targeted therapies are available, there is no clear justification for stratifying patients by EGFR status or excluding patients with low EGFR levels from trials with ZD1839 or other EGFR inhibitors.
This paper references
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
M. Ranson (2002)
Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced non-small-cell lung cancer (IDEAL 1)
M. Fukuoka (2002)
Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma.
M. Tateishi (1994)
Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission
A. Gschwind (2001)
Untangling the ErbB signalling network
Y. Yarden (2001)
Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.
R. Nicholson (1993)
Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
H. Iwase (1997)
Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
H. Kurokawa (2001)
Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways
G. Carpenter (1999)
Biological Predictors of Response to Radiotherapy in Head and Neck Cancer: Recent Advances and Emerging Perspectives
R. Corvò (2001)
Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease.
Z. Nešković-Konstantinović (1999)
Patterns of epidermal growth factor receptor amplification in malignant gliomas.
G. Sauter (1996)
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
J. Christensen (2001)
Variations of EGF-R surface expression in squamous cell carcinomas of the head and neck region.
R. Mandic (2001)
Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family.
C. Sartor (2000)
Epidermal growth factor-related peptides and their receptors in human malignancies.
D. Salomon (1995)
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR‐positive cancer cell lines with or without erbB2 overexpression
N. Anderson (2001)
EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.
J. Fischer-Colbrie (1997)
Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung.
M. Tateishi (1990)
The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study
J. Klijn (2004)
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
M. Moasser (2001)
Prospects for combining hormonal and nonhormonal growth factor inhibition.
A. Wakeling (2001)
Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
X. Chen (2000)
Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
P. Harari (2001)
Tyrosine kinase signalling in breast cancer
N. Hynes (2000)
The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy.
N. Magne (2001)
ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
D. Karunagaran (1996)
Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.
W. Xia (1999)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
C. Vogel (2002)
Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Y. Mizukami (1991)
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
F. Sirotnak (2000)
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
J. Albanell (2002)
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
C. Wikstrand (1995)
Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues.
D. Cohen (1994)
Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer
E. Filardo (2002)
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
R. Nishikawa (1994)
ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors*
R. Worthylake (1999)
Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer
S. Tsutsui (2004)
Enzyme immunoassay of human epidermal growth factor receptor (hEGFR).
R. Kumar (2001)
Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.
Y. Ohsaki (2000)
Tyrosine kinase signalling in breast cancer: Epidermal growth factor receptor - convergence point for signal integration and diversification
N. Prenzel (2000)
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.
J. Baselga (2000)
Co‐expression of epidermal growth factor receptor and transforming growth factor‐α predicts worse prognosis in breast‐cancer patients
Y. Umekita (2000)
Radioimmunohistochemistry of epidermal growth factor receptor in breast cancer.
K. W. Robertson (2002)
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.
R. Nicholson (2001)
Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
J. Newby (1997)
A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC)
R. Pérez-Soler (2001)
Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
V. Rusch (1997)
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.
M. Volm (1998)
Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.
J. Brabender (2001)
Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma.
E. Hsieh (2000)
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
F. Ciardiello (2000)
Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.
A. Knoop (2001)
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.
D. Moscatello (1995)
Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.
B. Voldborg (1997)
EGFR and cancer prognosis.
R. Nicholson (2001)
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
S. Moulder (2001)
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.
P. Birner (2001)
Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas.
V. Gorgoulis (1992)
This paper is referenced by
Clinicopathologic analysis of esophageal and cardiac cancers and survey of molecular expression on tissue arrays in Chaoshan littoral of China.
M. Su (2004)
Expression and amplification of therapeutic target genes in retinoblastoma
D. Bösch (2004)
Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
M. Cunningham (2008)
Riboflavin-Conjugated Multivalent Dendrimer Platform for Cancer-Targeted Drug and Gene Delivery
Pamela T Wong (2017)
Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis via degradation of epidermal growth factor receptor.
W. Dai (2014)
Gefitinib modulates stress fibers and tubular-like structure formation and attenuates angiogenesis in an in vivo chicken model of chorioallantoic membrane angiogenesis.
Tsung-Chieh Lin (2020)
Dichloroacetate potentiates tamoxifen-induced cell death in breast cancer cells via downregulation of the epidermal growth factor receptor
S. H. Woo (2016)
Development and Clinical Implementation of Reverse Phase Protein Microarrays for Protein Network Activation Mapping: Personalized Cancer Therapy
M. Pierobon (2012)
Benzofuran–appended 4-aminoquinazoline hybrids as epidermal growth factor receptor tyrosine kinase inhibitors: synthesis, biological evaluation and molecular docking studies
M. Mphahlele (2018)
The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery.
M. Alaoui-Jamali (2003)
Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways
A. Pickhard (2010)
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity
F. Finetti (2015)
7.08 – Kinase Inhibitors for Cancer
A. Mortlock (2007)
Genomic gain of the epidermal growth factor receptor harboring band 7p12 is part of a complex pattern of genomic imbalances in oral squamous cell carcinomas.
E. Gebhart (2004)
Targeting the epidermal growth factor receptor by erlotinib (Tarceva™) for the treatment of esophageal cancer
A. Sutter (2006)
The development of CAR design for tumor CAR-T cell therapy
Dandan Xu (2018)
Improvements and Applications of in situ Proximity Ligation Assays
Karin Grannas (2015)
Factors associated with effectiveness of and rash occurrence by EpidermalGrowth Factor Receptor Tyrosine Kinase Inhibitors in patients with non-small cell lung cancer
N. Bae (2008)
Kinase inhibitors in cancer therapy.
C. London (2004)
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
A. Awada (2012)
Studies on the Roles of PDGFRA and EGFR in the Classification and Identification of Therapeutic Targets for Human Gliomas
D. Chen (2013)
Rapid and homogeneous electrochemical detection by fabricating a high affinity bispecific antibody-enzyme complex using two Catcher/Tag systems.
H. Kimura (2020)
Pan‐HER—An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand‐induced EGFR homo‐ and heterodimers
Sofie Ellebæk (2016)
Label-free cell phenotypic assessment of the molecular mechanism of action of epidermal growth factor receptor inhibitors
Huayun Deng (2013)
EGF receptor as a therapeutic target.
A. Levitzki (2003)
The EGF receptor family as therapeutic targets in breast cancer.
M. Lemmon (2003)
Growing opportunities for adjuvant therapy of renal cell carcinoma: targeted drugs and vaccines
A. Rodriguez (2007)
Novel targeted therapies in head and neck cancer
M. B. Ferreira (2012)
Oncogenes and cancer.
C. Croce (2008)
Präklinische Evaluation des EGF-Rezeptor-Tyrosinkinase-Inhibitors "Gefitinib" an der A 253-Zelllinie bei Kopf- und Halstumoren
I. Klinik (2006)
Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers.
Lucimari Bizari (2006)
HSP 90 inhibitors induce desensitization of EGF receptor via p 38 MAPK-mediated phosphorylation at Ser 1046 / 1047 in human pancreatic cancer cells
S. Adachi ()See more